Study title: Azithromycin versus placebo for the treatment of HIV associated chronic lung disease; a randomized controlled trial

Lead Researcher(s): Grace McHugh

Funder(s): Medical Research Council of Norway

Partner(s):Malawi-Liverpool Wellcome Programme,Nuffield Department of Medicine, University of Oxford,IDM, University of Cape Town,University of Tromso - the Arctic University of Norway

Study aim(s)

One of the most common conditions of children with perinatal HIV is chronic lung disease, which may be caused by repeated infections that damage lung function over time. Breathe was a randomised placebo-controlled trial of the antibiotic azithromycin for adolescents with HIV and symptoms of chronic lung disease in Malawi and Zimbabwe. The trial is due to end in August 2019.

Study Design

Breathe was a randomised placebo-controlled trial of the antibiotic azithromycin for adolescents with HIV and symptoms of chronic lung disease in Malawi and Zimbabwe. The trial is due to end in August 2019.

Duration

2014-August 2019